Regenerative Medicine
US Clinics Now Offer Stem Cell and Exosome Therapy, Ending Need for Overseas Travel
Springs Rejuvenation has expanded stem cell and exosome therapies to five US cities, providing domestic access and eliminating the need for American patients to travel abroad for treatment.
Amerigo Scientific Launches Small Molecule Portfolio for Stem Cell Research and Therapy Manufacturing
Amerigo Scientific has introduced a comprehensive line of research-grade and GMP-grade small molecules to advance stem cell research, regenerative medicine, and cell therapy manufacturing, bridging fundamental research and clinical translation.
Regentis Biomaterials' GelrinC Targets Large Untapped Market for Off-the-Shelf Cartilage Repair
Regentis Biomaterials is advancing its GelrinC platform toward commercialization, aiming to fill the gap in FDA-approved off-the-shelf regenerative cartilage repair for the 470,000 annual U.S. knee cartilage damage cases.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with Novel Off-the-Shelf Solution
Regentis Biomaterials' GelrinC platform offers a potential first-in-class, ready-to-use knee cartilage repair treatment with superior pain relief and faster recovery, advancing through U.S. Phase III trials.
Springs Rejuvenation Brings Stem 3 Protocol to Austin, Offering Domestic Access to Regenerative Therapies
Springs Rejuvenation has launched its Stem 3 Protocol in Austin, Texas, providing patients with peptide therapy, exosome treatment, and advanced hair restoration under physician supervision, eliminating the need to travel abroad for these therapies.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with GelrinC
Regentis Biomaterials’ GelrinC offers a potential first-in-class, off-the-shelf solution for knee cartilage repair, with Phase III trial underway and CE Mark approval in Europe.
Regentis Biomaterials Advances GelrinC as Off-the-Shelf Solution for Knee Cartilage Repair, Targeting a 472,500-Procedure Gap
Regentis Biomaterials is developing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could fill a market gap as no approved off-the-shelf regenerative solution exists in the U.S., with a pivotal FDA trial now over 50% enrolled and a new manufacturing process boosting yield by 400%.
Springs Rejuvenation Opens Atlanta Clinic Offering Stem Cell Exosome Therapy and Advanced Hair Restoration
Springs Rejuvenation expands to Atlanta, providing integrated stem cell exosome therapy, advanced FUE hair restoration, and regenerative joint protocols under one roof in the Southeast.
BioStem Technologies to Present at LD Micro Invitational, Highlighting Regenerative Medicine Advances
BioStem Technologies will present at the 16th Annual LD Micro Invitational, showcasing its proprietary allograft technologies and expanding presence in regenerative medicine.
BioStem Technologies to Report First Quarter 2026 Results on May 14
BioStem Technologies will release Q1 2026 financial results on May 14, 2026, followed by a conference call and webcast at 4:30 PM ET, offering investors insight into the company's performance and growth trajectory in regenerative medicine.
Lionheart Health to Showcase Regenerative Technology at Prestigious Medical Innovation Forum
Lionheart Health's upcoming presentation at the Octane Medical Innovation Forum highlights the company's groundbreaking work in organ regeneration and healthspan longevity technologies, signaling significant advancements in the medical aesthetics and aging management industries.
Cellular Therapeutics Market Poised for Rapid Growth, Investors Eye Key Innovators
The global cell therapy market is projected to expand from $7.43 billion to $47.72 billion by 2034, with companies like Adia Nutrition, Fate Therapeutics, Pluri Inc., and Ginkgo Bioworks leading innovative developments in regenerative medicine and cellular technologies.
BioRestorative Therapies Advances Stem Cell Treatments for Chronic Pain and Metabolic Diseases
BioRestorative Therapies is developing innovative stem cell therapies targeting chronic lower back pain, obesity, and type 2 diabetes, potentially offering new treatment options for millions suffering from these conditions.
Creative Biolabs Expands Induced Pluripotent Stem Cell Research Services
Creative Biolabs introduces comprehensive induced pluripotent stem cell (iPSC) services, offering researchers advanced tools to accelerate stem cell therapy research and development across multiple disease domains.